AR061743A1 - Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro - Google Patents
Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierroInfo
- Publication number
- AR061743A1 AR061743A1 ARP070102915A ARP070102915A AR061743A1 AR 061743 A1 AR061743 A1 AR 061743A1 AR P070102915 A ARP070102915 A AR P070102915A AR P070102915 A ARP070102915 A AR P070102915A AR 061743 A1 AR061743 A1 AR 061743A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclic
- aryl
- group
- unsubstituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2857—Seizure disorders; Epilepsy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Uso de una clase de compuestos péptidos para tratar enfermedades asociadas con hiperexcitabilidad. Uso de una clase de compuestos péptidos para tratar enfermedades asociadas con disfuncion de un canal de hierro. Reivindicacion 1: Uso de un compuesto que tiene la formula (1) en donde, R es hidrogeno, alquilo, alquenilo, alquinilo, arilo, aril alquilo heterocíclico, heterocíclico alquilo, alquilo heterocíclico, cicloalquilo o cicloalquil alquilo, y R está insustituido o está sustituido con al menos un grupo aceptor de electrones, y/o al menos un grupo donante de electrones; R1 es hidrogeno o alquilo, alquenilo, alquinilo, aril alquilo, arilo, heterocíclico alquilo, alquilo heterocíclico, heterocíclico, cicloalquilo, cicloalquil alquilo, cada uno insustituido o sustituido con al menos un grupo donante de electrones y/o al menos un grupo aceptor de electrones; R2 y R3 son independientemente hidrogeno, alquilo, alquenilo, alquinilo, alcoxi, alcoxialquilo, aril alquilo, arilo, halo, heterocíclico, heterocíclico alquilo, alquilo heterocíclico, cicloalquilo, cicloalquil alquilo, o Z-Y en donde R2 y R3 pueden estar insustituidos o sustituidos con al menos un grupo aceptor de electrones y/o al menos un grupo donante de electrones; y en donde el heterocíclico en R2 y R3 es furilo, tienilo, pirazolilo, pirrolilo, metilpirrolilo, imidazolilo, indolilo, tiazolilo, oxazolilo, isotiazolilo, isoxazolilo, piperidilo, pirrolinilo, piperazinilo, quinolilo, triazolilo, tetrazolilo, isoquinolilo, benzofurilo, benzotienilo, morfolinilo, benzoxazolilo, tetrahidrofurilo, piranilo, indazolilo, purinilo, indolinilo, pirazolindinilo, imidazolinilo, imidazolindinilo, pirrolidinilo, furazanilo, N-metilindofilo, metilfurilo, piridazinilo, pirimidinilo, pirazinilo, piridilo, epoxi, aziridino, oxetanilo, azetidinilo, o cuando N está presente en el heterocíclico, un N-oxido del mismo; Z es O, S, S(O)a, NR4, NR'6, PR4 o un enlace químico; Y es hidrogeno, alquilo, arilo, aril alquilo, alquenilo, alquinilo, halo, heterocíclico, heterocíclico alquilo, alquil heterocíclico e Y puede estar insustituido o sustituido con al menos un grupo donante de electrones y/o al menos un grupo aceptor de electrones, con la condicion de que, cuando Y es halo, Z es un enlace químico, o ZY conjuntamente son NR4NR5R7, NR4OR5, ONR4R7, OPR4R5, PR4OR5, SNR4R7, NR4SR7, SPR4R5, PR4SR7, NR4PR5R6, PR4NR5R7, N+R5R6R7, NR4C(=O)R5, SC(=O)R5, NR4C(=O)OR5, SC(=O)OR5 o NR4NR5- C(=O)OR6; R'6 es hidrogeno, alquilo, alquenilo o alquinilo y que puede estar insustituido o sustituido con al menos un grupo aceptor de electrones y/o al menos un grupo donante de electrones; R4, R5 y R6 son independientemente hidrogeno, alquilo, arilo, aril alquilo, alquenilo, o alquinilo, en donde R4, R5 y R6 pueden estar independientemente insustituidos o sustituidos con al menos un grupo aceptor de electrones y/o al menos un grupo donante de electrones; R7 es R6 o COOR8 o COR8, en donde R7 puede estar insustituido o sustituido con al menos un grupo aceptor de electrones y/o al menos un grupo donante de electrones; R8 es hidrogeno o alquilo, o aril alquilo, y el grupo arilo o alquilo puede estar insustituido o sustituido con al menos un grupo aceptor de electrones y/o al menos un grupo donante de electrones; n es 1-4; y a es 1-3; o una sal farmacéuticamente aceptable del mismo, caracterizado porque es para la preparacion de una composicion farmacéutica para la prevencion, alivio y/o tratamiento de una enfermedad asociada con hiperexcitabilidad.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06013655A EP1873527A1 (en) | 2006-06-30 | 2006-06-30 | Method for identifying CRMP modulators |
EP06021469 | 2006-10-12 | ||
EP06021470A EP1920780A1 (en) | 2006-10-12 | 2006-10-12 | Peptide compounds for the treatment of hyperexcitability disorders |
EP06024241A EP1925314A1 (en) | 2006-11-22 | 2006-11-22 | Pharmaceutical composition with synergistic anticonvulsant effect |
Publications (1)
Publication Number | Publication Date |
---|---|
AR061743A1 true AR061743A1 (es) | 2008-09-17 |
Family
ID=38721381
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102916A AR061744A1 (es) | 2006-06-30 | 2007-06-29 | Metodo para identificar proteinas mediadoras de respuesta a colapsina |
ARP070102915A AR061743A1 (es) | 2006-06-30 | 2007-06-29 | Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102916A AR061744A1 (es) | 2006-06-30 | 2007-06-29 | Metodo para identificar proteinas mediadoras de respuesta a colapsina |
Country Status (14)
Country | Link |
---|---|
US (3) | US9308183B2 (es) |
EP (3) | EP2345455B1 (es) |
JP (1) | JP2009541397A (es) |
KR (1) | KR20090030329A (es) |
CN (2) | CN101466390B (es) |
AR (2) | AR061744A1 (es) |
AU (1) | AU2007263936A1 (es) |
BR (1) | BRPI0713994A2 (es) |
CA (1) | CA2654652C (es) |
EA (1) | EA200900098A1 (es) |
ES (1) | ES2569333T3 (es) |
MX (1) | MX2009000249A (es) |
TW (2) | TW200819138A (es) |
WO (2) | WO2008000513A2 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1243263B1 (en) * | 2001-03-21 | 2002-11-27 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain |
US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
EA013591B1 (ru) * | 2004-04-16 | 2010-06-30 | Шварц Фарма Аг | Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd) |
EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
PL1781276T3 (pl) * | 2004-08-27 | 2010-11-30 | Ucb Pharma Gmbh | Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy |
EP1642889A1 (en) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
EP1873527A1 (en) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
CN101466390B (zh) | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
EA027836B1 (ru) | 2006-06-15 | 2017-09-29 | ЮСиБи ФАРМА ГМБХ | Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение |
US20100260716A1 (en) * | 2007-10-23 | 2010-10-14 | Ucb Pharma Gmbh | Compounds for treating demyelination conditions |
US8933065B2 (en) * | 2008-04-01 | 2015-01-13 | The University Of North Carolina At Chapel Hill | N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents |
CN102051408B (zh) * | 2009-11-04 | 2012-07-04 | 高新 | 用于前列腺癌转移早期诊断的试剂盒 |
EP3766485A1 (en) | 2010-12-02 | 2021-01-20 | UCB Pharma GmbH | Once daily formulation of lacosamide |
EP2468261A1 (en) | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation of lacosamide |
US8779355B2 (en) | 2011-12-28 | 2014-07-15 | Quest Diagnostics Investments, Inc. | Methods for detecting lacosamide by mass spectrometry |
KR101361546B1 (ko) * | 2012-07-09 | 2014-02-13 | 전남대학교산학협력단 | 유전성 골격근 이온통로병 원인 예측방법을 수행하기 위한 컴퓨터 프로그램이 수록된 컴퓨터로 읽을 수 있는 기록매체 및 이를 실행시키는 장치 |
WO2014139539A1 (en) * | 2013-03-15 | 2014-09-18 | Syddansk Universitet | Inhibitor of dpysl3/crmp4 for treatment of bone loss |
US20180369207A1 (en) * | 2015-12-11 | 2018-12-27 | Aarhus Universitet | Rufinamide for use in the treatment of myotonia |
BR112018012870A2 (pt) | 2015-12-30 | 2018-12-04 | Adamas Pharmaceuticals Inc | métodos e composições para o tratamento de transtornos relacionados à crise |
JP2019525947A (ja) | 2016-06-01 | 2019-09-12 | エムスリー・バイオテクノロジー・インコーポレイテッドM3 Biotechnology, Inc. | 化合物 |
CN106551900A (zh) * | 2016-12-05 | 2017-04-05 | 北京万全德众医药生物技术有限公司 | 一种拉科酰胺口服溶液及其制备工艺 |
US20200188469A1 (en) * | 2017-04-04 | 2020-06-18 | The Trustees Of Columbia University In The City Of New York | Compounds and methods for inhibiting cdk5 alleviate cardiac phenotypes in timothy syndrome and related conditions |
US11278634B1 (en) | 2021-02-12 | 2022-03-22 | Extrovis Ag | Stable parenteral composition of lacosamide |
AU2022288145A1 (en) * | 2021-06-11 | 2024-01-04 | Lupin Atlantis Holdings Sa | Extended-release compositions of mexiletine for oral administration |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2319338A1 (fr) * | 1975-08-01 | 1977-02-25 | Synthelabo | Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent |
US4736866B1 (en) * | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US5378729A (en) * | 1985-02-15 | 1995-01-03 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
US5585358A (en) | 1993-07-06 | 1996-12-17 | Yissum Research Development Corporation Of The Hebrew University Of Jerusalem | Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents |
US5780589A (en) * | 1994-11-30 | 1998-07-14 | The United States Of America As Represented By The Department Of Health And Human Services | Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof |
EP0840612A1 (en) * | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
US5773475A (en) * | 1997-03-17 | 1998-06-30 | Research Corporation Technologies, Inc. | Anticonvulsant enantiomeric amino acid derivatives |
US6277825B1 (en) * | 1996-07-22 | 2001-08-21 | University Of Utah Research Foundation | Use of conantokins for treating pain |
US6589994B1 (en) | 1996-08-30 | 2003-07-08 | Nps Pharmaceuticals, Inc. | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound |
US6048899A (en) | 1997-03-17 | 2000-04-11 | Research Corporation Tech., Inc. | Anticonvulsant enantiomeric amino acid derivatives |
WO2002002620A2 (en) * | 2000-06-29 | 2002-01-10 | Mayo Foundation For Medical Education And Research | Crmp-5 (collapsin response-mediator protein) encoding nucleic acid, polypeptide and uses thereof |
CA2418455A1 (en) | 2000-08-17 | 2002-02-21 | Teva Pharmaceutical Industries, Ltd. | Valproic acid derivatives for the treatment of pain |
EP1486205B1 (en) * | 2000-08-25 | 2007-10-17 | Research Corporation Technologies, Inc | Use of anticonvulsant aminoacids for the treatment of migraine |
US20020119944A1 (en) * | 2000-11-09 | 2002-08-29 | Michelle Aguera | Use of Ulip-and/or Ulip2 in the treatment of myelin disorders |
EP1339669B1 (en) | 2000-11-21 | 2008-06-04 | UCB Pharma, S.A. | N-alkylated gaba compounds, processes for their preparation and their use as medicaments |
PT1243262E (pt) | 2001-03-20 | 2006-10-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica |
EP1243263B1 (en) | 2001-03-21 | 2002-11-27 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain |
ZA200204907B (en) * | 2001-06-26 | 2003-03-03 | Univ Nat Taiwan | Collapsin Response Mediator Protein-1. |
AU2002341090A1 (en) * | 2001-09-07 | 2003-03-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of a protein of the crmp family for treating diseases related to the immune system |
US7687080B2 (en) * | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
AU2004207009A1 (en) | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Use of sodium channel modulators for treating gastrointestinal tract disorders |
WO2004066990A2 (en) | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using sodium channel modulators |
WO2005051413A2 (en) * | 2003-11-26 | 2005-06-09 | Novartis Ag | Disease associated genes |
AU2004294714B2 (en) | 2003-12-02 | 2009-12-10 | Ucb Pharma Gmbh | Novel use of peptide compounds for treating central neuropathic pain |
EP1537862A1 (en) | 2003-12-02 | 2005-06-08 | Schwarz Pharma Ag | Novel use of peptide compounds for treating central neuropathic pain |
EP1541138A1 (en) * | 2003-12-05 | 2005-06-15 | Schwarz Pharma Ag | Novel use of peptide compounds for treating status epilepticus or related conditions |
US20060009384A1 (en) * | 2003-12-05 | 2006-01-12 | David Rudd | Novel use of peptide compounds for treating status epilepticus or related conditions |
US20070042969A1 (en) | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
EP1579858A1 (en) | 2004-03-26 | 2005-09-28 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
US20100256179A1 (en) | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
EA013591B1 (ru) | 2004-04-16 | 2010-06-30 | Шварц Фарма Аг | Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd) |
EP1604654A1 (en) | 2004-05-18 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating dyskinesia |
EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
EP1604656A1 (en) * | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
US7427601B2 (en) | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
PL1781276T3 (pl) | 2004-08-27 | 2010-11-30 | Ucb Pharma Gmbh | Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy |
EP1642889A1 (en) | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
US20060252749A1 (en) | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
MX2007009070A (es) | 2005-01-28 | 2007-09-12 | Sanol Arznei Schwarz Gmbh | (spm 927) para terapia supletoria de esquizofrenia. |
US20070043120A1 (en) | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
US20070048372A1 (en) | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
EP1754476A1 (en) | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
CN101466390B (zh) | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
EA027836B1 (ru) | 2006-06-15 | 2017-09-29 | ЮСиБи ФАРМА ГМБХ | Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение |
EP1873527A1 (en) | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
US20100260716A1 (en) | 2007-10-23 | 2010-10-14 | Ucb Pharma Gmbh | Compounds for treating demyelination conditions |
DK2352721T3 (da) * | 2008-11-07 | 2013-07-01 | Ucb Pharma Gmbh | Hidtil ukendt fremgangsmåde til fremstilling af aminosyrederivater |
US8969620B2 (en) * | 2010-10-01 | 2015-03-03 | Ucb Pharma Gmbh | Process for the preparation of amino acid derivatives |
EP2487152A1 (en) * | 2010-11-17 | 2012-08-15 | UCB Pharma GmbH | Process for the preparation of Lacosamide including resolution of O-methyl-DL-serine |
EP3766485A1 (en) * | 2010-12-02 | 2021-01-20 | UCB Pharma GmbH | Once daily formulation of lacosamide |
EP2468261A1 (en) * | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation of lacosamide |
-
2007
- 2007-06-15 CN CN200780022239.7A patent/CN101466390B/zh not_active Expired - Fee Related
- 2007-06-29 JP JP2009517011A patent/JP2009541397A/ja active Pending
- 2007-06-29 EP EP11002768.7A patent/EP2345455B1/en not_active Revoked
- 2007-06-29 KR KR1020097001931A patent/KR20090030329A/ko not_active Application Discontinuation
- 2007-06-29 US US12/306,953 patent/US9308183B2/en not_active Expired - Fee Related
- 2007-06-29 EA EA200900098A patent/EA200900098A1/ru unknown
- 2007-06-29 EP EP07764967.1A patent/EP2046386B1/en not_active Not-in-force
- 2007-06-29 CA CA2654652A patent/CA2654652C/en not_active Expired - Fee Related
- 2007-06-29 BR BRPI0713994-2A patent/BRPI0713994A2/pt not_active Application Discontinuation
- 2007-06-29 US US12/306,950 patent/US20090241205A1/en not_active Abandoned
- 2007-06-29 AR ARP070102916A patent/AR061744A1/es unknown
- 2007-06-29 MX MX2009000249A patent/MX2009000249A/es not_active Application Discontinuation
- 2007-06-29 EP EP07764966A patent/EP2038659A2/en not_active Withdrawn
- 2007-06-29 AU AU2007263936A patent/AU2007263936A1/en not_active Abandoned
- 2007-06-29 AR ARP070102915A patent/AR061743A1/es unknown
- 2007-06-29 CN CN201310404840.XA patent/CN103494795A/zh active Pending
- 2007-06-29 WO PCT/EP2007/005806 patent/WO2008000513A2/en active Application Filing
- 2007-06-29 WO PCT/EP2007/005805 patent/WO2008000512A2/en active Application Filing
- 2007-06-29 ES ES11002768.7T patent/ES2569333T3/es active Active
- 2007-07-02 TW TW096123999A patent/TW200819138A/zh unknown
- 2007-07-02 TW TW096123998A patent/TW200819744A/zh unknown
-
2013
- 2013-09-10 US US14/022,342 patent/US20140066515A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0713994A2 (pt) | 2012-11-20 |
US20100324144A1 (en) | 2010-12-23 |
EP2345455B1 (en) | 2016-03-16 |
WO2008000512A2 (en) | 2008-01-03 |
TW200819744A (en) | 2008-05-01 |
CA2654652A1 (en) | 2008-01-03 |
KR20090030329A (ko) | 2009-03-24 |
WO2008000513A3 (en) | 2008-09-04 |
CN101466390B (zh) | 2014-03-12 |
EP2046386B1 (en) | 2014-07-23 |
US20090241205A1 (en) | 2009-09-24 |
US9308183B2 (en) | 2016-04-12 |
WO2008000513A2 (en) | 2008-01-03 |
CN103494795A (zh) | 2014-01-08 |
EP2038659A2 (en) | 2009-03-25 |
CN101466390A (zh) | 2009-06-24 |
TW200819138A (en) | 2008-05-01 |
WO2008000512A3 (en) | 2008-03-06 |
AR061744A1 (es) | 2008-09-17 |
EP2046386A2 (en) | 2009-04-15 |
EA200900098A1 (ru) | 2009-06-30 |
AU2007263936A1 (en) | 2008-01-03 |
CA2654652C (en) | 2015-06-02 |
MX2009000249A (es) | 2009-01-23 |
EP2345455A1 (en) | 2011-07-20 |
JP2009541397A (ja) | 2009-11-26 |
US20140066515A1 (en) | 2014-03-06 |
ES2569333T3 (es) | 2016-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR061743A1 (es) | Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro | |
AR061475A1 (es) | Compuestos peptidicos para tratar status epilepticus refractario | |
AR050612A1 (es) | Novedoso uso de compuestos peptidos para tratar dolor por cancer de huesos, dolor inducido por quimioterapia y nucleosidos y composicion farmaceutica | |
AR061476A1 (es) | Composicion farmaceutica con efecto anticonvulsivo sinergico | |
AR049940A1 (es) | Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor | |
AR056467A1 (es) | USO DE COMPUESTOS PEPTíDICOS PARA TRATAR DOLOR MUSCULAR | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
BR112016012506A8 (pt) | combinações farmacêuticas, seus usos, e uso de um portador de dados | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
ATE375793T1 (de) | Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen | |
BR112014015482A2 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
EA201990235A1 (ru) | ТВЕРДЫЕ ФОРМЫ СТИМУЛЯТОРА sGC | |
Zhou et al. | Effect of metabotropic glutamate 5 receptor antagonists on morphine efficacy and tolerance in rats with neuropathic pain | |
EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
BR112012020377A8 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
MY170991A (en) | Dosing regimens of celgosivir for the treatment of dengue | |
ES2879375T3 (es) | Procedimientos de manejo del miedo condicionado con antagonistas del receptor de neuroquinina | |
ES2761311T3 (es) | Tratamiento terapéutico | |
AR050097A1 (es) | Uso de compuestos peptidicos para tratar dolor en neuropatia diabetica dolorosa | |
AR050196A1 (es) | Uso de compuestos peptidicos para tratar esclerosis lateral amiotrofica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |